Mission Statement, Vision, & Core Values (2026) of Renhe Pharmacy Co., Ltd.

Renhe Pharmacy Co., Ltd. (000650.SZ), established in 2001, has built a commanding presence in China's healthcare landscape as a manufacturer and distributor of OTC medications-specializing in capsules, tablets and ointments that address common colds, skin diseases and pediatric health-while operating both wholesale and retail channels and committing to strategic growth and international expansion; guided by a mission to improve public health through high-quality products and ethical transparency, a vision to enhance community well-being and professional leadership in pharmaceutical distribution, and core values centered on integrity, customer-centricity, innovation, community engagement, sustainability and operational excellence, Renhe's organizational compass aligns product development, R&D investment and distribution strategies to meet evolving consumer needs and strengthen its role as a trusted partner in healthcare

Renhe Pharmacy Co., Ltd. (000650.SZ) - Intro

• Core product categories: cold & flu remedies, dermatological ointments/creams, pediatric supplements and symptomatic relief medications.
• Sales channels: proprietary retail outlets, third-party pharmacies, hospital channels, e-commerce and bulk wholesale distribution.
• Geographic footprint: strong domestic penetration across provincial markets with strategic plans for selective international exports and partnerships.

• Mission: Provide safe, effective and accessible OTC medications that improve everyday health for Chinese families, emphasizing quality control, affordability and rapid market availability.
• Vision: Become a top-tier consumer healthcare and OTC pharmaceutical brand from China, recognized for product safety, innovation and scalable distribution both domestically and in targeted overseas markets.
• Core values: Patient safety, scientific integrity, continuous innovation, operational excellence and responsible commercialization.

• Quality & compliance-upgrading GMP-certified production lines and digital batch traceability to reduce recalls and strengthen regulatory alignment.
• Portfolio optimization-focus on high-frequency OTC categories (cold remedies, dermatology, pediatric) while pruning low-margin SKUs.
• Channel expansion-scale e-commerce and modern retail partnerships to raise urban penetration; deepen wholesale reach to county-level pharmacies.
• R&D and product innovation-incremental reformulations, pediatric-friendly dosage forms, and value-added combination products to drive SKU premiumization.
• Internationalization-targeted export entry into neighboring Asian markets and distribution alliances for branded OTC lines.

• R&D reinvestment: R&D spend of RMB 112 million (≈2.2% of revenue) demonstrates a commitment to product development consistent with a mission of continual innovation and quality.
• Profitability vs. accessibility: Net margin pressures from competitive OTC pricing are balanced by a gross margin near 34%, allowing for affordable pricing while sustaining operations.
• Capital allocation: Capital expenditures focused on production upgrades and quality systems support the mission of safe, reliable medicines.

• Board oversight: periodic KPI reviews linking executive compensation to quality, regulatory compliance and sustainable margin targets.
• Supplier governance: audited supplier qualification and onsite inspections to ensure raw-material safety and traceability.
• Community & patient focus: targeted pediatric safety campaigns and patient education programs to build trust in OTC therapies.

Renhe Pharmacy Co., Ltd. (000650.SZ) - Overview

• To improve the health and well‑being of individuals through accessible, high‑quality pharmaceutical products and patient‑oriented services.
• To prioritize customer satisfaction and align operations with long‑term objectives aimed at market leadership in retail and proprietary medicines.
• To guide strategic decisions so that every action contributes to enhancing public health and therapeutic outcomes.
• To be a trusted healthcare partner, offering a broad portfolio that addresses chronic, acute and preventive care needs.
• To uphold ethical practices, regulatory compliance and transparency in business operations and stakeholder communications.
• To continuously improve product quality, distribution efficiency and service delivery to lead in the pharmaceutical value chain.

• To become one of China's leading integrated pharmaceutical and retail healthcare groups with best‑in‑class service, product quality and innovation.
• To expand nationwide access to essential medicines and consumer health products while advancing community pharmacy services.
• To leverage digital channels and supply‑chain integration for superior patient experience and operational resilience.

• Patient‑Centricity - decisions grounded in safety, efficacy and patient needs.
• Integrity - transparent, compliant and ethical conduct across all businesses.
• Quality - rigorous standards in manufacturing, sourcing and retailing.
• Innovation - continuous improvement of products, services and processes.
• Collaboration - partnerships with healthcare providers, suppliers and regulators to improve outcomes.
• Responsibility - corporate social responsibility and community health engagement.

• Product Quality: GMP and supplier audits aligned to ethical sourcing and regulatory compliance, reducing recall risk and protecting patients.
• Customer Satisfaction: Retail KPI programs, loyalty platforms and in‑store counseling to improve adherence and repeat purchase rates.
• Market Leadership: Targeted M&A and store expansion in underserved regions to increase market share and distribution density.
• Transparency & Governance: Regular public disclosure of financials and governance practices to maintain stakeholder trust.

• Increase same‑store sales by 6-8% year‑over‑year through service upgrades and digital channels.
• Grow proprietary product contribution to revenue to 20% within three years to improve margins.
• Maintain R&D and quality spend at levels that ensure product lifecycle renewal and regulatory compliance.

• Operational cash flow generation and a conservative debt profile enable capex for store modernization and supply‑chain automation.
• Shareholder returns and reinvestment decisions are balanced against the mission of long‑term public health impact.
• For a deeper financial breakdown and investor‑centric metrics, see: Breaking Down Renhe Pharmacy Co., Ltd. Financial Health: Key Insights for Investors

Renhe Pharmacy Co., Ltd. (000650.SZ) - Mission Statement

• Deliver reliable, compliant pharmaceutical distribution and retail services to enhance public well-being.
• Promote community health education and preventative care initiatives.
• Maintain ethical sourcing, supply-chain transparency, and regulatory compliance.
• Invest in logistics, digitalization, and service quality to improve access across urban and rural areas.

• Domestic expansion of retail and distribution networks to increase coverage and accessibility.
• Strategic cross-border partnerships and selective international distribution to extend influence.
• Community-centered programs to measure and improve health outcomes in served regions.
• Continuous investment in staff training and professionalization to uphold service standards.

• Strengthen distribution efficiency via logistics hubs and cold-chain capabilities to support chronic and specialty drug delivery.
• Expand product portfolio to include higher-value generics and OTC health products, increasing therapeutic breadth.
• Accelerate digital transformation-omnichannel retail, telepharmacy support, and supply-chain traceability-to improve customer access and safety.
• Deepen community engagement through health screening, education campaigns, and partnerships with local healthcare providers.

Renhe Pharmacy Co., Ltd. (000650.SZ) - Vision Statement

• Integrity: Renhe Pharmacy upholds strict compliance and transparency across procurement, distribution, and retail operations, with internal audit coverage expanded to 100% of regional distribution centers.
• Customer-centricity: The company emphasizes personalized services across its retail network and digital channels to raise customer retention and lifetime value-supported by loyalty programs that contributed materially to same-store sales growth.
• Innovation: Sustained R&D and product innovation focus on high-demand OTC, traditional Chinese medicine (TCM) derivatives, and health supplements-backed by dedicated R&D units and strategic partnerships with research institutes.
• Community engagement: Corporate initiatives prioritize public-health campaigns, vaccination drives, and free health screenings in underserved regions, aligning retail presence with social responsibility.
• Sustainability: Renhe integrates green logistics, energy-efficient store designs, and reduced packaging initiatives to lower operational carbon intensity across distribution and retail networks.
• Excellence: Quality control systems, supplier qualification, and standardized retail protocols aim to deliver consistent product safety and service quality across all outlets.

• Operational focus areas to realize the vision:
  • Expand digital health services (e-commerce, teleconsultation, loyalty analytics) to boost omnichannel penetration.
  • Scale private-label and high-margin OTC lines via targeted R&D and supplier integration.
  • Optimize logistics and green practices to reduce costs and environmental footprint per store.
  • Deepen community programs to strengthen brand trust and local market share.